Pharmaceuticals, Biotechnology and Life Sciences
With semaglutide patents nearing expiry in key markets, Indian manufacturers and partners are mobilizing to introduce lower‑cost GLP‑1 alternatives, tapping…
Novo Nordisk’s mid‑stage “triple G” obesity candidate UBT251 showed up to ~19.7 % mean weight loss in a Chinese phase 2…
Novo Nordisk reports up to 19.7% mean weight loss in Phase 2 trial of triple agonist UBT251, expanding its next-generation obesity pipeline.
GREENSBORO, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) — Precise Bio, Inc. (“Precise Bio” or the “Company”), a clinical-stage regenerative medicine…
EMERYVILLE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) — XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members…
MIRAMAR, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company…
Management will participate in three upcoming investor healthcare conferencesSALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) — Myriad Genetics, Inc.…
Mechelen, Belgium; February 16, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification…
Army medic–turned–PharmD launches BetterLungs™ after losing relatives to smoking-related respiratory illnessSAN ANTONIO, Feb. 16, 2026 (GLOBE NEWSWIRE) — Betterbrand, a…
SAN DIEGO, CA, Feb. 16, 2026 (GLOBE NEWSWIRE) — Sapu Bioscience today announced advancements in its global IP portfolio supporting…